title: Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]meta-iodobenzylguanidine and [(111)In]DTPA pentetreotide.
abstract: Ocular metastases from carcinoid tumors are considered rare. They can be the primary presentation of a carcinoid tumor or develop during the course of the disease. The extent of distant metastases from carcinoid tumors correlates with poor prognosis and survival; early detection of metastasis may change the overall management. Radiopharmaceutical-labeled imaging techniques have been widely applied for the detection and localization of such lesions based on isotope uptake by neuroendocrine tumors. Routine application of these imaging modalities may reveal previously unsuspected lesions and may also be used to help stage the disease and to identify patients who may be treated with radiopharmaceuticals. Of 40 patients with carcinoid tumors reviewed in our department since we started routine scanning, we identified 6 (15%) who demonstrated ocular metastases: 5 with obvious lesions and 1 with presumed metastasis according to the results of nucleotide scanning. All 6 were negative on screening with [(123)I]meta-iodobenzylguanidine, whereas 3 of 4 who were screened with [(111)In]octreotide showed positive uptake. All patients responded well to radiotherapy and chemotherapy and did not require surgical treatment. The orbit and its contents appear to be a common site for carcinoid metastasis, and radiopharmaceutical imaging with labeled octreotide is useful in identifying many of these lesions.
authors.affiliation: Department of Endocrinology, St. Bartholomew's Hospital, London, United Kingdom EC1A 7BE.
authors.forename: A M
authors.initials: AM
authors.lastname: Isidori
authors.forename: G
authors.initials: G
authors.lastname: Kaltsas
authors.forename: V
authors.initials: V
authors.lastname: Frajese
authors.forename: B
authors.initials: B
authors.lastname: Kola
authors.forename: R A F
authors.initials: RA
authors.lastname: Whitelocke
authors.forename: P N
authors.initials: PN
authors.lastname: Plowman
authors.forename: K E
authors.initials: KE
authors.lastname: Britton
authors.forename: J P
authors.initials: JP
authors.lastname: Monson
authors.forename: A B
authors.initials: AB
authors.lastname: Grossman
authors.forename: G M
authors.initials: GM
authors.lastname: Besser
mesh_terms: D019797:3-Iodobenzylguanidine; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002276:Carcinoid Tumor / Q000000981:diagnostic imaging* / Q000473:pathology / Q000556:secondary*; D005134:Eye Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000556:secondary*; D005260:Female; D005654:Fundus Oculi; D006801:Humans; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D008297:Male; D008875:Middle Aged; D004369:Pentetic Acid / Q000031:analogs & derivatives; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals
chemical_list: C452379:DTPA pentetreotide; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine; D004369:Pentetic Acid